NEW YORK (360Dx) – Roche said today that it has obtained CE marking for the Ventana anti-ALK (D5F3) Rabbit Monoclonal Primary Antibody assay as a companion diagnostic to identify ALK-positive non-small cell lung cancer patients eligible for treatment with the Novartis drug Zykadia (ceritinib).

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.